| Literature DB >> 32117498 |
Dawid Groth1,2, Paulina Woźniewska1, Magdalena Olszewska1, Piotr Zabielski3, Jerzy R Ładny4, Jacek Dadan1, Anna Zalewska5, Agnieszka Błachnio-Zabielska6, Inna Diemieszczyk1, Adam Krętowski7, Hady Razak Hady1.
Abstract
INTRODUCTION: Laparoscopic sleeve gastrectomy (LSG) is recently a leading method in surgical treatment of morbid obesity. The metabolic outcome of intervention may be a result of many factors such as age, gender, preoperative weight loss and dietary restrictions. AIM: To evaluate gender-related differences in the results of LSG in 6-month follow-up.Entities:
Keywords: bariatric surgery; laparoscopic sleeve gastrectomy; obesity
Year: 2019 PMID: 32117498 PMCID: PMC7020728 DOI: 10.5114/wiitm.2019.86800
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.195
Characteristics of group differences at the time of LSG
| Parameter | Females | Males | |
|---|---|---|---|
| 53 (52%) | 48 (48%) | n/a | |
| Age, mean ± SD [years] | 40.8 ±11.24 | 43.48 ±10.16 | 0.216 |
| Body weight, mean ± SD [kg] | 124.70 ±17.94 | 155.48 ±24.86 | < 0.001 |
| BMI, mean ± SD [kg/m2] | 45.75 ±7.16 | 50.05 ±7.75 | 0.005 |
| Operative technique, | 0.387 | ||
| 2 cm and 32 Fr | 14 (26%) | 12 (25%) | |
| 2 cm and 40 Fr | 9 (17%) | 15 (31%) | |
| 6 cm and 32 Fr | 15 (28%) | 11 (23%) | |
| 6 cm and 40 Fr | 15 (28%) | 10 (21%) | |
| Insulin, median (IQR) [μU/dl] | 16.80 (12.70–26.40) | 23.10 (16.00–41.30) | 0.007 |
| Glucose, median (IQR) [IU/l] | 102.00 (95.00–108.00) | 112.00 (99.00–130.50) | 0.002 |
| HOMA-IR, median (IQR) | 4.10 (3.11–6.58) | 6.49 (3.99–12.81) | 0.001 |
| CRP, median (IQR) [mg/l] | 6.40 (3.60–9.30) | 7.92 (4.10–13.20) | 0.535 |
| HbA1c, median (IQR) % | 5.60 (5.40–5.90) | 5.80 (5.40–6.13) | 0.285 |
| Cholesterol, mean ± SD [mg/dl] | 203.89 ±34.42 | 203.40 ±37.55 | 0.540 |
| LDL, mean ± SD [mg/dl] | 138.60 ±34.25 | 138.5 ±36.11 | 0.708 |
| HDL, median (IQR) [mg/dl] | 45.00 (38.00–54.00) | 43.00 (36.50–50.50) | 0.081 |
| Triglycerides, median (IQR) [mg/dl] | 126.00 (101.00–191.00) | 165.50 (136.50–207.00) | 0.021 |
| ALT, median (IQR) [IU/l] | 25.00 (20.00–33.00) | 35.00 (29.50–46.00) | 0.001 |
| AST, median (IQR) [IU/l] | 22.00 (19.00–28.00) | 27.50 (20.50–41.00) | 0.013 |
ALT – alanine transaminase, AST – aspartate transaminase, BMI – body mass index, CRP – C-reactive protein, HbA1c – glycated hemoglobin, HDL – high-density lipoprotein, HOMA-IR – Homeostatic Model Assessment of Insulin Resistance Index, LDL – low-density lipoprotein.
Repetitive measurements of %EWL and %EBMIL
| Gender | %EWL 1 month | %EWL 3 months | %EWL 6 months | |
|---|---|---|---|---|
| Females | 21.14 ±7.78 | 38.64 ±10.84 | 56.32 ±15.93 | 0.026 |
| Males | 18.61 ±7.19 | 33.76 ±12.06 | 49.09 ±16.25 | |
| Females | 25.80 ±11.24 | 47.17 ±15.62 | 68.73 ±22.98 | 0.001 |
| Males | 20.64 ±8.26 | 37.33 ±13.47 | 54.30 ±18.22 |
%EBMIL – percentage of excess BMI loss, %EWL – percentage of excess weight loss.
Figure 1Means %EWL with 95%CI in follow-up
Figure 2Means %EBMIL with 95%CI in follow-up
Repetitive measurements of selected laboratory test results
| Parameter | Gender | 0 | 1 month | 3 months | 6 months | ||
|---|---|---|---|---|---|---|---|
| Insulin, median (IQR) [μU/dl] | Female | 16.80 (12.70–26.40) | 9.00 (7.00–14.40) | 7.60 (6.10–11.90) | 6.30 (5.10–9.40) | < 0.001 | 0.031 |
| Male | 23.10 (16.00–41.30) | 10.85 (8.15–20.30) | 10.10 (7.40–14.50) | 7.25 (5.60–13.90) | |||
| Glucose, median (IQR) [mg/dl] | Female | 102.00 (95.00–108.00) | 93.00 (88.00–100.00) | 90.00 (85.00–98.00) | 90.00 (87.00–96.00) | < 0.001 | 0.012 |
| Male | 112.00 (99.00–130.50) | 100.50 (91–112.50) | 99.00 (89.50–105.5) | 93.00 (88.00–100.00) | |||
| HOMA-IR, median (IQR) | Female | 4.10 (3.11–6.58) | 2.11 (1.56–3.30) | 1.66 (1.36–2.52) | 1.35 (1.11–2.02) | < 0.001 | 0.001 |
| Male | 6.49 (3.99–12.81) | 3.02 (2.01–5.26) | 2.52 (1.61–3.71) | 1.63 (1.22–3.38) | |||
| CRP, median (IQR) [mg/l] | Female | 6.40 (3.60–9.30) | 5.50 (5.30–5.80) | 4.60 (3.50–9.20) | 4.70 (2.60–8.70) | 0.382 | 0.534 |
| Male | 7.92 (4.10–13.20) | 7.15 (3.75–11.90) | 5.95 (4.40–9.90) | 5.05 (3.68–8.14) | |||
| HbA1c, median (IQR) % | Female | 5.60 (5.40–5.90) | 5.50 (5.30–5.80) | 5.40 (5.20–5.70) | 5.20 (5.10–5.60) | < 0.001 | 0.499 |
| Male | 5.80 (5.40–6.13) | 5.60 (5.25–5.90) | 5.50 (5.20–5.70) | 5.40 (5.10–5.60) | |||
| Cholesterol, mean ± SD [mg/dl] | Female | 203.89 ±34.42 | 184.00 ±35.71 | 186.83 ±29.36 | 190.15 ±31.55 | < 0.001 | 0.982 |
| Male | 203.40 ±37.55 | 181.71 ±29.34 | 186.35 ±31.07 | 187.75 ±33.57 | |||
| LDL, mean ± SD [mg/dl] | Female | 138.60 ±34.25 | 128.64 ±38.16 | 131.21 ±31.60 | 132.62 ±31.16 | 0.005 | 0.784 |
| Male | 138.5 ±36.11 | 128.69 ±31.55 | 133.18 ±30.33 | 137.73 ±29.18 | |||
| HDL, median (IQR) [mg/dl] | Female | 45.00 (38.00–54.00) | 40.00 (34.00–48.00 | 48.00 (39.00–52.00) | 51.00 (44.00–58.00) | < 0.001 | 0.683 |
| Male | 43.00 (36.50–50.50) | 34.00 (29.00–47.00) | 46.00 (38.00–54.00) | 51.5 (41.50–62.00) | |||
| Triglycerides, median (IQR) [mg/dl] | Female | 126.00 (101.00–191.00) | 134.00 (108.00–172.00) | 123.00 (99.00–156.00) | 122.00 (93.00–145.00) | < 0.001 | 0.417 |
| Male | 165.50 (136.50–207.00) | 159.5 (119.00–196.50) | 147.00 (116.00–185.00) | 144.00 (92.50–166.50) | |||
| ALT, median (IQR) [IU/l] | Female | 25.00 (20.00–33.00) | 29.00 (20.00–39.00) | 20.00 (16.00–31.00) | 18.00 (13.00–21.00) | < 0.001 | 0.194 |
| Male | 35.00 (29.50–46.00) | 35.50 (26.00–56.50) | 24.50 (21.00–34.50) | 21.00 (17.00–26.00) | |||
| AST, median (IQR) [IU/l] | Female | 22.00 (19.00–28.00) | 26.00 (18.00–36.00) | 21.00 (17.00–26.00) | 16.00 (13.00–22.00) | < 0.001 | 0.840 |
| Male | 27.50 (20.50–41.00) | 30.50 (21.50–45.00) | 25.00 (20.00–30.00) | 19.00 (15.00–27.00) |
ALT – alanine transaminase, AST – aspartate transaminase, BMI – body mass index, CRP – C–reactive protein, F – females, HbA1c – glycated hemoglobin, HDL – high–density lipoprotein, HOMA-IR – Homeostatic Model Assessment of Insulin Resistance Index, LDL – low–density lipoprotein.